Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple ...

Pfizer—the maker of Paxlovid—has begun ... instead of making lots of compounds and profiling them in the laboratory, which is a slower process. For example, Allerton says, their models can ...

This can be completed at home. This programme offers a two-week intensive opportunity to train and learn essential molecular and cellular biological laboratory techniques in world class facilities ...

Nirmatrelvir [PF-07321332], which originated in Pfizer laboratories, is designed to block the activity of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate.

After I have presented the key tasks I faced when creating "ALLKA 4D Rating", I will move on to comparing Johnson & Johnson and Pfizer and choose the winner in the category "the most promising ...